Blueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by Needham & Company LLC
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by research analysts at Needham & Company LLC from a “moderate buy” rating to a “hold” rating in a research note issued on Monday, MarketBeat Ratings reports. They presently have a $130.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price target indicates […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by research analysts at Needham & Company LLC from a “moderate buy” rating to a “hold” rating in a research note issued on Monday, MarketBeat Ratings reports. They presently have a $130.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price target indicates […]
